Please login to the form below

Not currently logged in
Email:
Password:

SGLT inhibitor

This page shows the latest SGLT inhibitor news and features for those working in and with pharma, biotech and healthcare.

Sanofi exits Zynquista alliance with Lexicon

Sanofi exits Zynquista alliance with Lexicon

The drug is a dual inhibitor of SGLT1 and SGLT2 and was thought to work by reducing glucose absorption in the gastrointestinal tract and glucose reabsorption by the kidneys, as well ... Issues surrounding the higher rate of diabetic ketoacidosis (DKA) in

Latest news

  • NICE recommends MSD’s diabetes drug Steglatro NICE recommends MSD’s diabetes drug Steglatro

    drug. Steglatro is one of the competitors in the sodium-glucose cotransporter-2 (SGLT-2) inhibitor drugs, which are now becoming standard therapy in managing type 2 diabetes (T2D) patients in ... In the UK, the treatment is priced at £29.40 for 28 days,

  • The year of the blockbuster The year of the blockbuster

    Biktarvy (tenofovir alafenamide emtricitabine bictegravir) from Gilead:Gilead’s HIV triplet comprising the nucleoside reverse transcriptase inhibitor tenofovir alafenamide, the nucleoside reverse transcriptase inhibitor emtricitabine and the novel

  • Novo’s diabetes pill defeats Merck’s Januvia in trial Novo’s diabetes pill defeats Merck’s Januvia in trial

    Comparing oral semaglutide to Merck &Co’s DPP-4 inhibitor Januvia (sitagliptin), PIONEER 7 investigated the efficacy and safety of the GLP-1 inhibitor in people with type 2 diabetes. ... PIONEER 4 saw the enrolment of 711 people with type 2 diabetes

  • FDA panel backs CV claims for Novo Nordisk's Victoza FDA panel backs CV claims for Novo Nordisk's Victoza

    Victoza is the second drug to get a recommendation for improving cardiovascular outcomes in type 2 diabetics after Eli Lilly and Boehringer Ingelheim's SGLT-2 inhibitor Jardiance (empagliflozin), which had ... Merck &Co failed to win FDA approval for a

  • AZ gets US approval for diabetes combo Qtern AZ gets US approval for diabetes combo Qtern

    Qtern is a fixed dose combination product based on the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) and SGLT2 inhibitor Farxiga/Forixiga (dapagliflozin). ... The approval of Qtern is good news for patients who may benefit from

More from news
Approximately 1 fully matching, plus 21 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Langland

We love what we do and we think it shows.It shows in the work we do, the space we work...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics